Bioxytran Inc. (OTCQB: BIXT) announced results from a Phase 1b/2a clinical study of its oral antiviral drug ProLectin-M in hospitalized ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE